UCB Selects Medidata Clinical Cloud® to Support Patient-Centric Drug Development
April 26 2017 - 6:25AM
Business Wire
Medidata’s Cutting-Edge Technology Platform to
Drive Operational Excellence and Patient Value for Global
Biopharma
Medidata (NASDAQ:MDSO), the leading global
provider of cloud-based solutions and data analytics for clinical
research, today announced that UCB has selected the Medidata
Clinical Cloud® as its enterprise technology platform.
The Brussels-based global biopharmaceutical company will
leverage Medidata’s end-to-end cloud platform to improve
operational excellence and better engage patients across UCB’s
diverse clinical development portfolio. As part of the multi-year
agreement, UCB plans to utilize Medidata’s data management and
targeted monitoring capabilities with the goal of improving
clinical data quality and availability; and reducing trial costs
and cycle times. UCB also plans to leverage Medidata’s mobile
health (mHealth) solutions to capture more objective, continuous
data in a manner that reduces patient burden and adds value to
patient lives.
“UCB is committed to transforming the lives of people with
severe diseases, and we are leveraging both scientific advances and
cutting-edge technology to do so,” said Tero Laulajainen, Head of
Global Clinical Sciences and Operations (GCSO) at UCB. “The
Medidata Clinical Cloud will help us get an earlier and more
complete view of patients while they undergo therapy, enabling us
to explore new models for clinical development and identify
insights to drive future innovation.”
In adopting a single, unified platform, UCB will have faster
access to clinical data and reduced complexity across its pipeline
of neurological and immunological candidates. The global
biopharmaceutical company will leverage multiple solutions within
the Medidata Clinical Cloud platform, including: Medidata Rave®,
Medidata Coder®, Safety Gateway, and Medidata TSDV. UCB plans to
use Medidata’s mHealth solution for electronic patient-reported
outcomes (ePRO) on a study-by-study basis.
“UCB’s patient-led, science-driven research and development is
making a meaningful difference in people’s lives, and Medidata is
proud to provide the technology and analytical insights to propel
its R&D efforts,” said Mike Capone, Medidata’s chief operating
officer. "Medidata’s unified cloud platform is transforming global
drug development, and we are uniquely positioned to support the
business and innovation goals of UCB and nearly 850 other life
sciences customers.”
Connect with Medidata
- Read our blog, Geeks Talk Clinical
- Tweet this: .@UCB_news turns to unified
@Medidata #tech to improve clinical #data quality, enhance #patient
engagement & more: http://ow.ly/w61j30bb5J3
- Follow us on Twitter: @Medidata
- Find us on LinkedIn
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global
biopharmaceutical company focused on the discovery and development
of innovative medicines and solutions to transform the lives of
people living with severe diseases of the immune system or of the
central nervous system. With more than 7,500 people in
approximately 40 countries, the company generated revenue of € 4.2
billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB).
Follow us on Twitter: @UCB_news.
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
nearly 850 global pharmaceutical companies, innovative biotech,
diagnostic and device firms, leading academic medical centers, and
contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 17 of the world's
top 25 global pharmaceutical companies and is used by 16 of the top
20 medical device developers— from study design and planning
through execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170426005624/en/
Medidata SolutionsInvestors:Anthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Dick Wolfe, +1
646-483-2988dwolfe@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024